![Richard Fagan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Fagan
Director/Miembro de la Junta en Novalgen Ltd. .
Cargos activos de Richard Fagan
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Miembro de la Junta | - | - |
Historial de carrera de Richard Fagan
Antiguos cargos conocidos de Richard Fagan.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Freeline Therapeutics Ltd.
![]() Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | - | - |
Estadísticas
Internacional
Reino Unido | 3 |
Operativa
Director/Board Member | 2 |
Sectorial
Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Freeline Therapeutics Ltd.
![]() Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Richard Fagan
- Experiencia